NCT02170181: Clinical Registry for Oligometastatic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients can have up to 6 sites of active extracranial disease (outside of the brain) with a maximum of 7 cm diameter

Comments are closed.

Up ↑